UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Molecular and cellular neuroscience, 2021-07, Vol.114, p.103641-103641, Article 103641

2021

Volltextzugriff (PDF)

Idalopirdine, a 5-HT6 antagonist in Phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: the observed case analyses of the Phase II study

Neurobiology of aging, 2016-03, Vol.39, p.S2-S3

2016

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults

Journal of clinical pharmacology, 2024-08

2024

Volltextzugriff (PDF)

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Neuroscience letters, 2021-05, Vol.754, p.135894-135894, Article 135894

2021

Volltextzugriff (PDF)

A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer’s Disease: Idalopirdine in Phase III (PL02.006)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Animal models of stroke: do they have value for discovering neuroprotective agents?

Trends in pharmacological sciences (Regular ed.), 2003-08, Vol.24 (8), p.402-408

2003

Volltextzugriff (PDF)

Poster Number: NR 16 - A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III

The American journal of geriatric psychiatry, 2016-03, Vol.24 (3), p.S147-S148

2016

Volltextzugriff (PDF)

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Alzheimer's & dementia, 2020-12, Vol.16, p.n/a

2020

Volltextzugriff (PDF)

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains: Human neuropathology/amyloid

Alzheimer's & dementia, 2020-12, Vol.16 (S2)

2020

Volltextzugriff (PDF)

A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III

The American journal of geriatric psychiatry, 2016-03, Vol.24 (3), p.S147-S148

2016

Volltextzugriff (PDF)

Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals

BMC ophthalmology, 2017-12, Vol.17 (1), p.269-269, Article 269

2017

Volltextzugriff (PDF)

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke

Critical care medicine, 2004, Vol.32 (1), p.241-245

2004

Volltextzugriff (PDF)

Cerebral and cerebellar activation in correlation to the action-induced dystonia in Writer's cramp

Movement disorders, 1998-05, Vol.13 (3), p.497-508

1998

Volltextzugriff (PDF)

Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059

Pharmacology & therapeutics (Oxford), 2003-12, Vol.100 (3), p.195-214

2003

Volltextzugriff (PDF)

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results

Stroke (1970), 2002-01, Vol.33 (1), p.122-129

2002

Volltextzugriff (PDF)

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus

Diabetic medicine, 2000-03, Vol.17 (3), p.181-189

2000

Volltextzugriff (PDF)

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia

Journal of neurology, neurosurgery and psychiatry, 1998-01, Vol.64 (1), p.6-12

1998

Volltextzugriff (PDF)

Subthreshold Transpupillary Thermotherapy Reduces Experimental Choroidal Neovascularization in the Mouse without Collateral Damage to the Neural Retina

Investigative ophthalmology & visual science, 2004-06, Vol.45 (6), p.1969-1974

2004

Volltextzugriff (PDF)

Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force

The Journal of Prevention of Alzheimer's Disease, 2024, Vol.11 (1), p.56-64

2024

Volltextzugriff (PDF)

Photodynamic Therapy of Experimental Choroidal Neovascularization in the Mouse

Current eye research, 2006, Vol.31 (9), p.765-774

2006

Volltextzugriff (PDF)

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

The Journal of Prevention of Alzheimer's Disease, 2023, Vol.10 (3), p.418-425

2023

Volltextzugriff (PDF)

Vision‐related function after low‐dose transpupillary thermotherapy versus photodynamic therapy for neovascular age‐related macular degeneration

Acta ophthalmologica (Oxford, England), 2010-06, Vol.88 (4), p.426-430

2010

Volltextzugriff (PDF)

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results

Neurology, 2001-10, Vol.57 (7), p.1199-1205

2001

Volltextzugriff (PDF)

A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration

British journal of ophthalmology, 2008-06, Vol.92 (6), p.757-761

2008

Volltextzugriff (PDF)

Tolerability of NXY-059 at higher target concentrations in patients with acute Stroke

Stroke (1970), 2003-02, Vol.34 (2), p.482-487

2003

Volltextzugriff (PDF)

1 – 25 von 56

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(49)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease

Idalopirdine, a 5-HT6 antagonist in Phase III development as adjunctive therapy to cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: the observed case analyses of the Phase II study

Safety, Tolerability, and Pharmacokinetics of Single Doses of Exidavnemab (BAN0805), an Anti‐α‐Synuclein Antibody, in Healthy Western, Caucasian, Japanese, and Han Chinese Adults

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer’s Disease: Idalopirdine in Phase III (PL02.006)

Animal models of stroke: do they have value for discovering neuroprotective agents?

Poster Number: NR 16 - A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains: Human neuropathology/amyloid

A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III

Mapping standard ophthalmic outcome sets to metrics currently reported in eight eye hospitals

Early impairment in consciousness predicts mortality after hemispheric ischemic stroke

Cerebral and cerebellar activation in correlation to the action-induced dystonia in Writer's cramp

Nitrones as neuroprotective agents in cerebral ischemia, with particular reference to NXY-059

Clomethiazole Acute Stroke Study in ischemic stroke (CLASS-I): final results

Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus

A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport® and Botox®in the treatment of cervical dystonia

Subthreshold Transpupillary Thermotherapy Reduces Experimental Choroidal Neovascularization in the Mouse without Collateral Damage to the Neural Retina

Neuropsychiatric Symptoms in AD: Clinical Trials Targeting Mild Behavioral Impairment: A Report from the International CTAD Task Force

Photodynamic Therapy of Experimental Choroidal Neovascularization in the Mouse

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

Vision‐related function after low‐dose transpupillary thermotherapy versus photodynamic therapy for neovascular age‐related macular degeneration

The Clomethiazole Acute Stroke Study in tissue-type plasminogen activator-treated stroke (CLASS-T): final results

A prospective randomised study on low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration

Tolerability of NXY-059 at higher target concentrations in patients with acute Stroke

Suchergebnisse filtern